Aska Pharmaceutical Signs License With Sosei On Emergency Contraception Drug
This article was originally published in PharmAsia News
Executive Summary
Aska Pharmaceutical signed a license agreement with Sosei Oct. 21 and obtained exclusive rights to market SOH-075, an emergency contraception pill Sosei in-licensed from French Laboratoire HRA Pharma. SOH-075 completed Phase III trials in Japan and an approval is expected by the early half of 2009. According to the agreement, Sosei will receive a ¥300 million upfront payment, as well as potential milestone and royalty payments. Sosei will apply for the new drug approval and Aska will market the drug and conduct post-market surveillance. (Click here for more - Japanese language
You may also be interested in...
Will Japan Embrace Plan B Pill? Sosei Submits NDA For First Emergency Contraceptive Pill
Tokyo-based biopharmaceutical firm Sosei submitted an NDA for Norlevo (levonorgestrel), Japan's first emergency contraceptive pill. The filing puts Japan one step further to joining a list of 60 countries that have approved the so called "Plan B" or "morning-after pill.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.